PLRX
Pliant Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Bearish Engulfing
Ample Liquidity
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PLRX
Pliant Therapeutics, Inc.
A clinical stage biopharmaceutical company that developing novel therapies for fibrosis and related diseases
260 Littlefield Avenue, South San Francisco, CA 94080
--
Pliant Therapeutics, Inc., was incorporated in June 2015 under the laws of the State of Delaware. The company is a clinical-stage biopharmaceutical company dedicated to the discovery and development of new therapies for the treatment of fibrosis. Their initial focus was on treating fibrosis by inhibiting integrin-mediated TGF-β activation. Leveraging their deep understanding of fibrosis biology, as well as their expertise in medicinal chemistry and translational medicine, the company has developed a suite of proprietary tools designed to quickly and effectively discover and reduce the risk of product candidates. Their wholly-owned lead drug candidate, PLN-74809, is an oral small molecule dual selective inhibitor of integrin, which the company is developing for the treatment of idiopathic pulmonary fibrosis or IPF, primary sclerosing cholangitis or PSC.
Company Financials
EPS
PLRX has released its 2025 Q3 earnings. EPS was reported at -0.43, versus the expected -0.52, beating expectations. The chart below visualizes how PLRX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
